Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSmithers, B.M.-
dc.contributor.authorFahey, P.P.-
dc.contributor.authorCorish, T.-
dc.contributor.authorGotley, D.C.-
dc.contributor.authorFalk, G.L.-
dc.contributor.authorSmith, G.S.-
dc.contributor.authorKiroff, G.K.-
dc.contributor.authorClouston, A.D.-
dc.contributor.authorWatson, D.I.-
dc.contributor.authorWhiteman, D.C.-
dc.identifier.citationMedical Journal of Australia, 2010; 193(10):572-577-
dc.description.abstractOBJECTIVE: To document presenting symptoms, investigations and management for Australian patients with oesophageal adenocarcinoma (OAC), gastro-oesophageal junction adenocarcinoma (GOJAC) and oesophageal squamous cell carcinoma (OSCC). DESIGN, SETTING AND PARTICIPANTS: Cross-sectional study of a population-based sample of 1100 Australian patients aged 18-79 years with histologically confirmed oesophageal cancer diagnosed in 2002-2005, using data from cancer registries and treatment centres, supplemented with clinical information collected through medical record review in 2006-2007 and mortality information collected in 2008. MAIN OUTCOME MEASURES: Prevalence of primary symptoms, and staging investigations and treatment modalities used. RESULTS: The primary presenting symptom was dysphagia, which was self-reported by 41%, 39% and 48% of patients with OAC, GOJAC and OSCC, respectively. Less common symptoms were reflux, chest pain, bleeding and weight loss. All patients underwent endoscopy, most had a staging computed tomography scan (OAC 93%, GOJAC 95% and OSCC 93%), and about half had positron emission tomography scans (OAC 51%, GOJAC 44% and OSCC 42%). Pretreatment tumour stage was reported in 25% of records, and could be derived from results of investigations in a further 23%, but the remaining half lacked sufficient information to ascribe a pretreatment stage. Curative treatments were attempted for 60% of OAC, 88% of GOJAC and 65% of OSCC patients. Surgery was performed on 52% of OAC, 83% of GOJAC and 41% of OSCC patients. About two-thirds of surgical patients received additional therapies. CONCLUSIONS: With anticipated increases in oesophageal cancer incidence, the resources required to diagnose and manage patients with oesphageal cancer are also likely to rise. Our data provide a baseline from which to plan for the future care of patients with cancers of the oesophagus.-
dc.description.statementofresponsibilityBernard M Smithers, Paul P Fahey, Tracie Corish, David C Gotley, Gregory L Falk, Garett S Smith, George K Kiroff, Andrew D Clouston, David I Watson and David C Whiteman-
dc.publisherAustralasian Medical Publishing Company-
dc.rights© Australasian Medical Publishing Company-
dc.subjectEsophagogastric Junction-
dc.subjectCarcinoma, Squamous Cell-
dc.subjectEsophageal Neoplasms-
dc.subjectNeoplasm Staging-
dc.subjectSex Distribution-
dc.subjectCross-Sectional Studies-
dc.subjectDeglutition Disorders-
dc.titleSymptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australia-
dc.typeJournal article-
dc.identifier.orcidKiroff, G.K. [0000-0003-0523-5311]-
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.